Get App
Download App Scanner
Scan to Download
Advertisement

PI Industries Shares In Focus As Motilal Oswal Remains Bullish Despite Weak Q4 Results — Check Target Price

Motilal Oswal remains cautiously optimistic on FY27, supported by a strong order book, committed customer offtake plans, and the planned launch of over 5+ new molecules in the CSM business, which should accelerate PI Industries' growth in H2 FY27.

PI Industries Shares In Focus As Motilal Oswal Remains Bullish Despite Weak Q4 Results — Check Target Price
PI's CSM business witnessed a sharp slowdown in FY26 due to weak industry demand, elevated channel inventories globally, and customers adopting a cautious just-in-time procurement strategy, resulting in a volume decline.
(Photo: NDTV Profit/ AI generated image)
STOCKS IN THIS STORY
PI Industries Ltd.
--

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Domestic brokerage firm Motilal Oswal largely maintains its FY27/FY28 earnings estimates for PI Industries Ltd. and has reiterated its Buy rating with a target price of Rs 3,500 (based on 33x FY28E EPS, i.e. a discount of ~10% to the company's six-year historical P/E at 37x).

PI Industries reported a weak quarter as revenue declined 12% YoY, primarily due to a 15% YoY dip in the CSM business, attributed to the global slowdown and cautious customer scheduling (volume declined 14% YoY).

Domestic Agri also reported a revenue decline of 9% YoY, while the pharma business grew 23% YoY. Gross margins expanded 280bp YoY due to a better product mix and operational efficiency, while lower volumes led to adverse operating leverage, thereby resulting in an overall Ebitda margin contraction of 400bp YoY.

Going forward, the brokerage remain cautiously optimistic on FY27, supported by a strong order book, committed customer offtake plans, and the planned launch of over 5+ new molecules in the CSM business, which should accelerate growth in 2HFY27.

In addition, the Biologicals pipeline and potential inorganic opportunities continue to strengthen the growth outlook. 

Click on the attachment to read the full report:

Motilal Oswal Pi Industries Q4 Results Review.pdf
VIEW DOCUMENT

ALSO READ: Samvardhana Motherson Q4 Review: Motilal Oswal Ups Target Price On Long-Term Growth Outlook — Check Upside

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Add NDTV Profit As Google Preferred Source
Loading PDF...